Antigen Aggregation Decides the Fate of the Allergic Immune Response

Nadja Zaborsky, Marietta Brunner, Michael Wallner, Martin Himly, Tanja Karl, Robert Schwarzenbacher, Fatima Ferreira and Gernot Achatz

*J Immunol* 2010; 184:725-735; Prepublished online 7 December 2009;
doi: 10.4049/jimmunol.0902080
http://www.jimmunol.org/content/184/2/725

Supplementary Material
http://www.jimmunol.org/content/suppl/2010/01/11/jimmunol.0902080.DC1

References
This article cites 46 articles, 12 of which you can access for free at:
http://www.jimmunol.org/content/184/2/725.full#ref-list-1

Subscription
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts

Errata
An erratum has been published regarding this article. Please see next page or:
/content/190/8/4432.full.pdf
Antigen Aggregation Decides the Fate of the Allergic Immune Response

Nadja Zaborsky,* Marietta Brunner,* Michael Wallner,* Martin Himly,* Tanja Karl,† Robert Schwarzenbacher,‡ Fatima Ferreira,* and Gernot Achatz*

Previously, defined naturally occurring isoforms of allergenic proteins were classified as hypoallergens and therefore suggested as an agent for immunotherapy in the future. In this paper, we report for the first time the molecular background of hypoallergenicity by comparing the immunological behavior of hyperallergenic Betula verrucosa major Ag 1a (Bet v 1a) and hypoallergenic Bet v 1d, two isoforms of the major birch pollen allergen Betula verrucosa 1. Despite their cross-reactivity, Bet v 1a and Bet v 1d differ in their capacity to induce protective Ab responses in BALB/c mice. Both isoforms induced similar specific IgE levels, but only Bet v 1d expressed relevant titers of serum IgGs and IgAs. Interestingly, hypoallergenic Bet v 1d activated dendritic cells more efficiently, followed by the production of increased amounts of Th1- as well as Th2-type cytokines. Surprisingly, compared with Bet v 1a, Bet v 1d-immunized mice showed a decreased proliferation of regulatory T cells. Crystallographic studies and dynamic light scattering revealed that Bet v 1d demonstrated a high tendency to form disulfide-linked aggregates due to a serine to cysteine exchange at residue 113. We conclude that aggregation of Bet v 1d triggers the establishment of a protective Ab titer and supports a rationale for Bet v 1d being a promising candidate for specific immunotherapy of birch pollen allergy. The Journal of Immunology, 2010, 184: 725–735.

Received for publication June 29, 2009. Accepted for publication November 3, 2009.

The sequence presented in this article has been submitted to the Protein Data Bank (OENB Grant 11710).

The online version of this article contains supplemental material.

Abbreviations used in this paper: AP, alkaline phosphatase; Bet v 1, Betula verrucosa major Ag 1; BMDC, bone marrow-derived dendritic cell; BPE, birch pollen extract; CBA, cytomtric bead array; DLS, dynamic light scattering; MHC II, MHC class II; Treg, regulatory T cell.

Copyright © 2010 by The American Association of Immunologists, Inc. 0022-1767/10$16.00

www.jimmunol.org/cgi/doi/10.4049/jimmunol.0902080
Bet v 1d is highly prone to form aggregates, stabilized by a disulfide bond because of the serine to cysteine exchange at position 113. From our experiments, we conclude that the allergenicity of an Ag is partially determined by its structural properties and intrinsic features, which dictates its ability to stimulate APCs.

Materials and Methods

Mice

BALB/c mice were obtained from Charles River Laboratories (Wilmington, MA) and C57BL/10ScNcr mice (deletion of the Tlr4 gene) from Max-Planck-Institut (Freiburg, Germany). Mice were bred and maintained in the animal facility at the University of Salzburg according to the institutional and national guidelines for animal care and use.

Expression and purification of recombinant proteins

Bet v 1a/d and Bet v 1d C113S protein expression (pET28b [Novagen, Madison, WI]) in Escherichia coli BL21 (DE3), grown in Luria-Bertani medium (25 mg/L kanamycin) at 37°C to an OD₆₀₀ of 0.8. After the addition of 0.5 mM isopropyl-β-D-thiogalactoside, expression of Bet v 1a was performed for 4 h at 37°C, and expression of Bet v 1b and Bet v 1d C113S was performed at 16°C for 18 h. Soluble Bet v 1a was purified under soluble conditions as described previously (10). Soluble Bet v 1d and Bet v 1d C113S were purified from nonclassical inclusion bodies by hydrophobic interaction chromatography using a Phenyl-Sepharose column (GE Healthcare, Vienna, Austria) followed by anion exchange chromatography using a DEAE-Sepharose column (GE Healthcare). Recombinant proteins were dialyzed against 10 mM sodium phosphate buffer (pH 7.4), freeze-dried, and stored at −20°C. Endotoxin content of recombinant proteins was < 3 EU/ mg protein as determined by Limulus amoebocyte lysate assay (Associates of Cape Cod, East Falmouth, MA). Bet v 1a/d, Bet v 1d C113S, and birch pollen extract (BPE, batch 012596101; Allergon, Göteborg, Sweden AB) were separated on a 4–12% gel and stained with Coomassie staining. Physicochemical parameters of Bet v 1 isoforms were determined as described elsewhere (11). Immunization experiments, Ag uptake, and BMDC stimulation assays as well as dimerization analysis were also conducted with Bet v 1a and d purchased from BioNay (Vienna, Austria), which gave similar results (Bet v 1a: lot no. 22; Bet v 1d: lot no. 08a).

Immunization and serum Ab measurement

BALB/c mice were immunized with 5 µg Bet v 1a/d and Bet v 1d C113S, or BPE formulated with aluminum hydroxide (Serva, Heidelberg, Germany), according to the manufacturer’s instructions. Vaccinations were given as two 100-µl s.c. injections administered bilaterally in the lumbar region and boosted on days 14, 21, and 42. Serum was taken on day 0, 14, 21, 42, and 49, and Ab titers were determined by ELISA and β-hexosaminidase release assays.

β-Hexosaminidase release assay

RBL-2H3 were plated (4 × 10⁵ cells/well) in 96-well and sensitized for 2 h with mouse sera. After washing the cells in Tyrode buffer (0.1% BSA; Life Technologies, Grand Island, NY), cross-linking was induced by 0.5 µg/ml Bet v 1a/d in Tyrode buffer for 30 min at 37°C. β-Hexosaminidase release was measured upon enzymatic cleavage of 4-methylumbelliferyl-N-acetyl-β-D-glucosaminide (Sigma-Aldrich, St. Louis, MO) in citrate buffer (0.1 M, pH 4.5) at 360 nm/465 nm. Values are expressed as a percentage of total cellular β-hexosaminidase release after the addition of 1% Triton X-100 (Sigma-Aldrich).

Bet v 1-specific ELISA

Nunc-96-well plates were coated with 250 ng/well Bet v 1a/d, Bet v 1d C113S, and BPE. Sera were diluted in PBS containing 0.1% BSA. Alkaline phosphatase (AP)-labeled rat anti-mouse IgE (BD Biosciences, San Jose, CA), mouse anti-human IgE-AP (BD Biosciences), goat anti-mouse IgG1-AP, goat anti-human IgG-AP (Zymed Laboratories, San Francisco, CA), goat anti-mouse IgG2a-AP, and goat anti-mouse IgA-AP (Southern Bio-technology Associates, Birmingham, AL) were added at a concentration of 1 µg/ml in PBS/0.1% BSA. Absorption was measured at 405 nm (492 nm as reference wavelength) after addition of p-nitrophenyl phosphate (Sigma-Aldrich). Results are expressed as arbitrary units in comparison with a pooled standard serum.

Generation and culture of BMDCs

BMDC precursors were harvested from femurs/tibias and were cultured in RPMI 1640 complete medium (10% FBS [Life Technologies], 2 mM L-glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin; PAA, Vienna, Austria) supplemented with 10 ng/ml GM-CSF (PeproTech, Rocky Hill, NJ). Cells were seeded in a concentration of 1 × 10⁶ cells/ml. After 3 d, 50% of the medium was replaced, and the cells were cultured for a total of 7 d. As confirmed by flow cytometry, the population of cells was predominantly CD11c positive.

Proliferation assay

Proliferation assays were initiated 1 wk following the booster vaccination. BMDCs were stimulated overnight with 3 µg/ml of the respective Ag. Erythrocytes were lysed with PharmLyse (BD Biosciences). CD4⁺ splenocytes were isolated (CD4⁺ T Cell Isolation Kit; Milleniy Biotech, Auburn, CA) subsequently CFSE stained (10 µM, Invitrogen) and cocultured with 1 × 10⁵ Bet v 1a/d-pulsed BMDCs in a 96-well plate in RPMI 1640 complete medium. At day 3, cells were stained according to the manufacturer’s recommendations. For intracellular cytokine staining, cells were preincubated with 1 µg/ml brefeldin A (Sigma-Aldrich) for 4 h prior to staining. The following Abs were used: anti-mouse FoxP3 (clone FJK-16s; -E Bioscience, San Diego, CA), anti-mouse CD25 allophycocyanin (clone: PGC1.5; -Bioscience), anti-mouse CD4 FITC (clone RM4-5; -Bioscience), anti-mouse CD4 allophycocyanin (clone RM4-5; Biolegend, San Diego, CA), anti-mouse IL-13 PE (clone eBio13A; -Bioscience), anti-mouse IFN-γ PE-Cy7 (clone XMG1.2; -Bioscience), or matching isotype controls (BD Biosciences/eBioscience) and analyzed by flow cytometry. Supernatants were collected at day 3 and stored at −80°C. Results from three individual mice in triplicate wells were combined to yield a mean ± SD for each immunization group.

In vitro stimulation of BMDC and Ag-uptake assay

BMDCs (2 × 10⁵) were loaded with 1.5 µg/ml Bet v 1a/d-FITC, Bet v 1d C113S-FITC, and OVA-FITC (Sigma-Aldrich) in RPMI 1640 complete medium at 37°C prior to labeling cells on ice with Abs against CD80 PE (clone 16-10A1), CD86 PE (clone GL1), MHC class II (MHC II)/MHC II-PE (clone M5/1415.2), CD11c-allophycocyanin or -FITC (clone HL3), or matching isotype controls (all from BD Biosciences) and CD70 PE (clone FR70), OX40 ligand (clone RM134L), IL-6 PE (clone MP5-20F3), and IL-12/IL23p40 PE (clone C15.6) (all from Biolegend). Bet v 1-FITC labeling was done by DRFZ Charité (Berlin, Germany) (FITC/ protein labeling ratio: Bet v 1a:3.6/Bet v 1d:3.2). For endocytosis measurements, Bet v 1a/d was conjugated with pHRoDo succinimidyl ester (Invitrogen, Carlsbad, CA), according to the instructions of the manufacturer. BMDCs were loaded with 1.5 µg/ml Bet v 1a/d − pHRoDo, and Ag endocytosis was analyzed as described above.

Cytokine analysis

The supernatants of BMDC-T cell cocultures were collected after 3 d, and specific levels of IL-2, IL-4, IL-5, IFN-γ, and TNF-α were determined using mouse Th1/Th2 cytokine cytometric bead array (CBA) (BD Biosciences) following the manufacturer’s instructions.

Flow cytometry

Data acquisition was performed on a FACSCantoII (BD Biosciences) and analyzed using FlowJo software. Statistical analyses were performed using paired/unpaired Student t test.

Generation of Bet v 1-specific hybridoma

Mice were immunized with a mixture of 2.5 µg Bet v 1d. Hybridomas were produced by fusing splenocytes with mouse myeloma cells (X63, Ag8.653). Screening for Ab production and isotype was done on microtitre plates against Bet v 1a/d, and positive clones were expanded by limited dilutions.

Crystallography

The Bet v 1 d protein was concentrated to 8 mg/ml by centrifugal ultrafiltration (Millipore, Bedford, MA) and crystallized using the vapor diffusion method. Crystals were grown in Hampton Crystal Screen 2 no. 13 (100 mM sodium acetate, 20 mM ammonium sulfate, and 30% PEG-MME 2000 [pH 4.6]). The crystals were measured at 100 K on an in-house rotating anode diffractometer (Bruker) equipped with a MAR345 image plate detector and an Oxford cryosystem. Crystals diffracted to 2.80Å and indexed in the monoclinic space group P2₁ with a = 32.97 Å, b = 57.01 Å, c = 38.93 Å, α =...
90.00, b = 92.27, and g = 90.00. Crystallographic data processing was performed with MOSFLM (12) and SCALA. The structure of Bet v 1d (Fig. 8) was determined by the molecular replacement method using program Molrep and the Bet v 1l structure as the search model (Protein Data Bank: 1fm4; Fold & Function Assignment System score - 94, sequence identity 97%) (13, 14). Structure refinement and model building was performed in REFMAC5 and O (15). The final model includes one Bet v 1d monomer (residues 3–158), 20 water molecules, and unidentified density in the central cavity. The Bet v 1d structure is very similar to Bet v 1a and superposes with a root mean square deviation of 0.36A. Structural differences are within the crystallographic error because of the lower resolution of Bet v 1d. The Ramachandran plot, produced by Procheck 3.4, shows that 96.8% of the residues are in the most favored regions and 3.2% in additional allowed regions. Model quality and rotamers were checked with NQ Flipper (16). Figures were prepared with PYMOL (DeLano Scientific, Palo Alto, CA). Coordinates and structure factors have been deposited at Protein Data Bank [www.pdb.org] with the accession number 3K78.

Mass spectrometry-based protein identification

Twenty micrograms of aqueous BPE separated on SDS gel (Bio-Rad, Hercules, CA). A protein band migrating at height of dimeric rBet v 1d (34 kDa) was cutout and digested using the ProteoExtract Trypsin Digestion Kit (Calbiochem, San Diego, CA). Tryptic peptides were separated by reversed-phase capillary HPLC coupled with an electrospray ionization–quadrupole time-of-flight mass spectrometer (CapLC-QT of Ultima Global, Micromass-Waters) as described previously (17). Resulting double mass spectrometry data were searched against SwissProt knowledgebase release of January 2008 using the ProteinLynx Global Server 2.2.5 software package (Waters, Milford, MA) with automatic data validation.

High-performance–size exclusion chromatography and dynamic light scattering

Homogeneity and aggregation behavior of Bet v 1a and Bet v 1d in solution were analyzed by high-performance–size exclusion chromatography online coupled with a TDA302 (Viscotek, Houston, TX) right-angle light scattering detector and by dynamic light scattering (DLS) on a DLS802 (Viscotek) system upon centrifugation for 10 min at 14,000 X g as described previously (11).

Results

Bet v 1 isoforms differ in their capacity to induce IgG1, IgG2a, and IgA responses in mice, which is independent of their relative abundance in pollen

Previous experiments indicated an intrinsic difference of Bet v 1 isoforms in their capacity to induce the production of serum IgE in humans (5). To exclude the possibility of allergenicity being simply a matter of differences in the relative abundance of the two isoforms, we first investigated the humoral response toward hyperallergenic Bet v 1a and hypoallergenic Bet v 1d in mice using a standardized immunization regimen. We primary immunized mice s.c. either with recombinant Bet v 1a, Bet v 1d, defined mixtures of Bet v 1a/d, or BPE, followed by three booster immunizations and determined specific serum Ab titers using ELISA and β-hexosaminidase secretion assays. In both assays, serum IgE titers did not significantly differ between Bet v 1a and Bet v 1d-immunized animals (Fig. 1B, lower graph, for RBL assay: 100% Bet v 1a, 48 ± 5.6%; 100% Bet v 1d, 30.5 ± 12.2%; and Fig. 1C, lower graph, for specific ELISA: day 0, 0.0 ± 0.0; day 21, 0.3 ± 0.7 versus 6.9 ± 6.3; day 42, 1.1 ± 0.7 versus 1.9 ± 1.8; day 49, 1.4 ± 1.2 versus 5.3 ± 5.7). The IgE levels shown in Fig. 1C, lower panel, were also analyzed by hexosaminidase release assay (Fig. 1E), proving that both assays yield to comparable results (Fig. 1E, upper graph: IgE levels at day 42, 11.48 ± 3.36% [Bet v 1a] versus 12.67 ± 6.27% [Bet v 1d]; lower graph: IgE levels at day 49: 25.44 ± 3.20% [Bet v 1a] versus 32.35 ± 10.33% [Bet v 1d]).

However, specific IgG1, IgG2a, and IgA titers were much higher in Bet v 1d-immunized mice (Fig. 1C upper graph, for specific IgG1: day 0, 0.0 ± 0.0; day 21, 0.7 ± 0.9 versus 0.0 ± 0.0; day 42, 0.5 ± 0.4 versus 0.03 ± 0.1; day 49, 2.1 ± 1.4 versus 0.2 ± 0.7). Titers were determined from pooled sera of individual mice and mean values are shown as bars ± SD. B–D. Mice were immunized with different mixtures of rBet v 1a and Bet v 1d or with BPE. The composition of each Bet v 1a/d mixture used for immunization is indicated. Specific IgG1 and IgE serum titers were determined by ELISA and β-hexosaminidase release assay at day 49, using an equimolar mixture of Bet v 1a/d as specific Ag. C. Mice were immunized with either Bet v 1a (dark gray circles) or Bet v 1d (C). Specific IgG1 and IgE serum titers were determined on days 0, 21, 42, and 49. (D) Specific IgA and IgG2a titers were determined from pooled sera of day 49 from mice described in C. E. Specific IgE titers from mice described in C were determined by β-hexosaminidase release assay on day 42 (upper panel) and day 49 (lower panel). Titers were determined from individual mice and mean values are shown as bars ± SD. B–D. Each mouse is represented by a circle (n = 5 or 8/group), and pooled sera are shown as bars. Values are shown as arbitrary units in comparison with a pooled standard serum. Mean values are given as dash ± SD; values of p are indicated in graph (unpaired Student t test).
Accordingly, we observed a tight correlation between the magnitude of the Bet v 1-specific IgG1 response and the ratio of Bet v 1d to Bet v 1a used for immunization (Fig. 1B, upper graph; 0% Bet v 1d, 0.351 ± 0.310; 10% Bet v 1d, 0.175 ± 0.261; 50% Bet v 1d, 2.159 ± 2.323; 90% Bet v 1d, 3.735 ± 2.091; 100% Bet v 1d, 3.127 ± 2.091; BPE, 0.123 ± 0.095). Immunization experiments with BPE consistently showed that the far more abundant occurrence of Bet v 1a in natural Bet v 1 (Bet v 1a: Bet v 1d = 35%: 10% [5]) led to an equally low IgG1 response as observed for Bet v 1a-immunized animals (BPE, 0.123 ± 0.095) (Fig. 1B, upper graph).

Cross-reactivity of Bet v 1 isoforms is comparable for IgG1 and IgE Abs

Next we tested the cross-reactivity of serum Abs toward Bet v 1a and Bet v 1d. Interestingly, we found that IgG1 and IgE Abs from Bet v 1a- or Bet v 1d-immunized mice were comparably reactive with both isoforms (Fig. 2: Bet v 1 a/d cross-reactive IgG1 of Bet v 1a-immunized mice, 0.2 ± 0.5 versus 0.4 ± 0.5 and Bet v 1d-immunized mice, 2.1 ± 1.4 versus 2.4 ± 1.1, respectively; Bet v 1a/d cross-reactive IgE of Bet v 1a-immunized mice, 22.6 ± 3.2 versus 21.8 ± 1.9 and Bet v 1d-immunized mice, 25.9 ± 2.2 versus 25.4 ± 1.8, respectively).

To more precisely elucidate whether cross-reactivity is either based on serum Abs that bind both isoforms or on a mixture of Bet v 1a- or Bet v 1d-specific Abs, we screened for hybridomas from mice immunized with a mixture of Bet v 1a and Bet v 1d. Analysis of five specific clones (isotypes: IgG1 and IgM) revealed that all mAbs tested reacted with both isoforms to a similar extent (Supplemental Table I).

We next asked whether cross-reactivity is restricted to our murine model or whether it is also observed in the human serum. We therefore analyzed serum IgE and IgG from four allergic individuals for specific binding toward recombinant Bet v 1a or Bet v 1d using ELISA. Again, we could clearly show that serum Abs from all tested allergic individuals react to a similar extent with both Bet v 1 isoforms (Supplemental Fig. 1), proving that data gained from our murine model can be applied to the human system (Supplemental Fig. 1: Bet v 1a and Bet v 1d-specific IgG levels, 0.410 ± 0.2 versus 0.348 ± 0.06; Bet v 1a- and Bet v 1d-specific IgE levels, 0.615 ± 0.35 versus 0.768 ± 0.54) (Supplemental Fig. 1).

Bet v 1 isoforms display distinct patterns of uptake by BMDCs

In order to understand the striking difference in IgG and IgA production between Bet v 1a- and Bet v 1d-immunized mice, we analyzed the response of DCs toward the two Bet v 1 isoforms. We generated mouse BMDCs and incubated them at physiological temperature with FITC-conjugated Bet v 1a and FITC-conjugated Bet v 1d, respectively. At defined time points, we stained the BMDCs on ice for the DC marker CD11c and determined the amount of FITC-conjugated Bet v 1a and d captured by BMDCs using flow cytometry. As shown in Fig. 3A, uptake of FITC-Bet v 1d occurred at much higher rate than of Bet v 1a. Upon incubation for 5 h, 17.2 ± 2.6% of the CD11c+ BMDCs were Bet v 1a positive as opposed to 32.4 ± 2.5% for Bet v 1d (p < 0.001). At 16 h of incubation, the difference in Ag uptake was even higher (13.2 ± 0.9% for Bet v 1a versus 35.8 ± 2.9% for Bet v 1d, p < 0.001; n = 9). LPS contamination of the recombinant Bet v 1 isoforms was excluded by limulus-assays (<3 EU/mg protein; data not shown). Nevertheless, also we performed the Bet v 1 uptake experiment with BMDCs from C57BL/10ScNcr mice, which lack the expression of TLR4, the innate receptor for LPS. Again, the uptake of Bet v 1a was significantly slower than the uptake of Bet v 1d, implying that LPS contamination and subsequent TLR4 activation is not responsible for the observed results (Fig. 3B: t = 5 h, 32.9 ± 3.5% Bet v 1a versus 52.3 ± 5.8% Bet v 1d, p = 0.004; t = 26 h, 12.0 ± 1.8% Bet v 1a versus 22.6 ± 2.1% Bet v 1d, p = 0.001; n = 3).

Additionally, we measured BMDC-mediated endocytosis of Bet v 1a and Bet v 1d after conjugation with pHrOdo, a rhodamine-based dye that is fluorescent at acidic environment, thus, being suitable for measuring endocytosis. As shown in Fig. 3C, the endocytosis of Bet v 1d-pHrOdo is much more efficient than of Bet v 1a-pHrOdo reflected in a higher percentage of pHrOdo-positive BMDCs 5 and 16 h postaddition of Ag (t = 5 h, 6.3 ± 1.0% Bet v 1a versus 17.8 ± 1.6% Bet v 1d, p < 0.001; t = 16 h, 28.9 ± 2.5% Bet v 1a versus 39.6 ± 1.9% Bet v 1d, p < 0.001; n = 5).

We also compared uptake of Bet v 1a/d with that of OVA as a model Ag (Supplemental Fig. 2). Therefore, we used OVA-FITC to stimulate BMDCs and determined the fraction of FITC-positive BMDCs after 26 h. We found that OVA was captured at similar efficacy as Bet v 1a, with 31.2 ± 2.2% of the BMDCs being positive for OVA-FITC at t = 26 h, 32.7 ± 4.2% compared to case of Bet v 1a-FITC (p = 0.2) and 48.12 ± 3.2% for Bet v 1d-FITC (p < 0.001) (Supplemental Fig. 2A). Also, expression of CD80 and MHC II on OVA-FITC–positive BMDCs was comparable with Bet v 1a (Supplemental Fig. 2B: CD80, 48.2 ± 8.3% [OVA] versus 42.9 ± 6.3% [Bet v 1a] p = 0.2 versus 85.1 ± 2.9% [Bet v 1d] and MHC II, 3.6 ± 0.9% [OVA] versus 5.6 ± 2.2% [Bet v 1a] p = 0.1 versus 13.3 ± 1.2% [Bet v 1d]).

The expression of activation markers and costimulatory cytokines in BMDCs is different depending on the Bet v 1 isoform used for stimulation

To further evaluate the pattern of BMDC activation in dependence on the Bet v 1 isoform, we examined the expression of activation markers CD80, CD86, and MHC II using flow cytometry. We incubated BMDCs for 0.5, and 16 h with FITC-Bet v 1a or FITC-Bet v 1d at 37˚C and subsequently determined the expression of CD80, CD86, and MHC II using PE-conjugated specific Abs. We observed significant differences in the expression profile of activation markers (Fig. 4). After 5 h of incubation with specific Ag, significantly fewer BMDCs were positive for CD80 (76.2 ± 1.1%) and CD86 (59.3 ± 4.7%), when stimulated with Bet v 1a as opposed to Bet v 1d-stimulated BMDCs (80.9 ± 1.1% and 69.0 ± 1.5%, respectively; p = 0.003 and p = 0.014). After 16 h, significantly higher MHC II and CD80 expression levels were measured for Bet v 1d-pulsed BMDCs (12.8 ± 3.5% and 5.7 ± 1.3%; p = 0.015; 82.8 ± 2.8% and 69.0 ± 4.8%, respectively; p = 0.006). Thus, Bet v 1d induces higher expression rates for all three measured activation markers.
FIGURE 3. Ag uptake of BMDCs. A, BMDCs (BALB/c) were incubated with either FITC-labeled Bet v 1a or Bet v 1d and uptake of Ag was determined. A representative FACS profile of BMDCs is shown. Cells were gated for live cells, and the percentage of Bet v 1a-FITC– or Bet v 1d-FITC–positive cells among the CD11c-positive population is indicated within each plot. B, BMDCs from C57BL/10ScNcr mice were incubated with FITC-labeled Bet v 1a or Bet v 1d, and internalization of specific Ag was monitored. Shown is the percentage of Bet v 1a (○)– and Bet v 1d (▲)–positive cells at 0, 5, and 16 h postincubation with specific Ag (n = 5). Mean ± SD; values of p (unpaired Student t test) are indicated in graph.

As CD80/86-independent costimulation of T cells can be achieved by the TNF-family members OX40L and CD70 on APCs (18), we also evaluated expression levels of these costimulatory molecules on BMDCs upon stimulation with either Bet v 1a or Bet v 1d. As shown in Supplemental Fig. 3, we could not detect any differences in OX40L or CD70 surface levels on BMDCs.

To more precisely determine BMDC activation, we also analyzed cytokine production upon Bet v 1 siRNA- or Bet v 1d of BMDCs. We therefore incubated BMDCs for 24 h with FITC-Bet v 1a or d at 37°C and subsequently determined intracellular levels of IL-6 and IL-12/23 by flow cytometry. Although levels of intracellular IL-12/23 in BMDCs were comparable between the differentially stimulated BMDCs, we interestingly observed an increase in IL-6 production upon incubation of BMDCs with Bet v 1a. Within the Bet v 1a-FITC–positive fraction, 8.93 ± 0.31% of BMDCs were positive for IL-6, whereas only 3.87 ± 0.72% (p = 0.002) of the Bet v 1d-FITC–positive BMDCs were IL-6–positive (Fig. 5).

Bet v 1a and Bet v 1d differ in their capacity to induce BMDC-mediated T cell proliferation and differentiation in vitro

We next asked, whether the distinct pattern of BMDC activation affects the proliferation of T cells in syngeneic BMDC–T cell coculture assays. MACS-sorted splenic CD4 Th cells from either Bet v 1a- or Bet v 1d-immunized mice were CFSE loaded and coincubated with Bet v 1a- or Bet v 1d-pulsed BMDCs. Interestingly, the elevated expression of activation markers on Bet v 1d-loaded BMDCs did not accompany with an overall increase of specific CD4+ T cell proliferation. When CD4 T cells from Bet v 1a-immunized animals were used, a substantial percentage of CD4 T cells proliferated in response to Bet v 1a-pulsed BMDCs (8.8 ± 2.9%) as well as to Bet v 1d-pulsed BMDCs (9.6 ± 4.2%) (Fig. 6A, 6C). Vice versa, CD4 T cells from Bet v 1d-immunized animals proliferated comparably in response to Bet v 1a (11.4 ± 4.9%) and Bet v 1d-pulsed BMDCs (9.9 ± 5.3%) (Fig. 6B, 6C) Without specific Ag, 6.5 ± 0.9% (T cells from Bet v 1a-immunized mice) and 6.9 ± 1.0% (T cells from Bet v 1d-immunized mice) of T cells proliferated (Fig. 6C).

To analyze in vitro differentiation into distinct Th1, Th2, and regulatory T cell (Treg) subsets, we additionally stained the cells from the coculture experiment with specific Abs against IFN-γ, IL-13, and CD25/FoxP3. The amount of IFN-γ–producing Th1 cells was slightly higher for T cells from Bet v 1a-immunized mice cocultured with Bet v 1d-stimulated BMDCs (0.6 ± 0.04% versus 0.5 ± 0.0%; p = 0.1 using Wilcoxon test) (Fig. 6D, upper panel, 6E). Most interestingly, the de novo generation of IL-13–positive Th2 cells was heightened significantly by Bet v 1d-pulsed BMDCs and peaked at four to five cell divisions (Bet v 1a-immunized mice: 1.4 ± 0.2% IL13+CD4+ cells for BMDCs restimulated with Bet v 1d versus 1.1 ± 0.1% IL13+CD4+ cells for BMDCs restimulated with Bet v 1a [p = 0.03 using Wilcoxon test] versus 0.3 ± 0.2% IL13+CD4+ cells for unstimulated BMDCs); Bet v 1d-immunized mice, 2.8 ± 0.3% IL13+CD4+ cells for BMDCs restimulated with Bet v 1d versus 2.1 ± 0.3% IL13+CD4+ cells for BMDCs restimulated with Bet v 1a [p = 0.03 using Wilcoxon t test] versus 0.6 ± 0.3% IL13+CD4+ cells for unstimulated BMDCs; Fig. 6D, second panel, 6F).
observed differences in BMDC stimulation, we determined the aggregates prominent compared with Bet v 1a.

Cell proliferation and cytokine secretion, is faster and more increased using Bet v 1d-pulsed BMDCs (Fig. 7: TNF-6 pg/ml; IL-4, 7.4 pg/ml versus 5.6 ± 1.0 pg/ml; IL-5, 202.3 ± 22.8 pg/ml versus 107.3 ± 14.0 pg/ml, whereas comparable amounts of TNF-α (60.4 ± 10.7 pg/ml versus 53.2 ± 11.5 pg/ml) and IL-2 (14.8 ± 4.8 pg/ml versus 15.1 ± 4.4 pg/ml) were determined. In coculture experiments using T cells from Bet v 1d-immunized mice, respectively; Fig. 6D, third panel, 6G).

In addition, we determined the cytokine profile from the supernatants of the coculture experiments using Th1/Th2 CBA. In T cells from Bet v 1a-immunized mice we observed an increase of IFN-γ, IL-4, and IL-5 in the coculture supernatants when re-stimulated with Bet v 1d (IFN-γ, 26.0 ± 2.9 pg/ml versus 9.8 ± 1.1 pg/ml; IL-4, 7.4 ± 1.0 pg/ml versus 5.6 ± 1.0 pg/ml; IL-5, 202.3 ± 22.8 pg/ml versus 107.3 ± 14.0 pg/ml), whereas comparable amounts of TNF-α (60.4 ± 10.7 pg/ml versus 53.2 ± 11.5 pg/ml) and IL-2 (14.8 ± 4.8 pg/ml versus 15.1 ± 4.4 pg/ml) were determined. In coculture experiments using T cells from Bet v 1d-immunized mice, all cytokines examined were significantly increased using Bet v 1d-pulsed BMDCs (Fig. 7: TNF-α, 101.9 ± 3.6 pg/ml versus 77.5 ± 9.8 pg/ml; IFN-γ, 96.0 ± 35.4 pg/ml versus 32.5 ± 11.5 pg/ml; IL-5, 490.2 ± 32.4 pg/ml versus 287.2 ± 18.8 pg/ml; IL-4, 49.8 ± 24.5 pg/ml versus 18.1 ± 7.6 pg/ml and IL-2, 71.6 ± 15.3 pg/ml versus 16.0 ± 5.2 pg/ml; n = 4).

We conclude that the overall immune response to Bet v 1d, reflected by DC Ag uptake and presentation as well as subsequent T cell proliferation and cytokine secretion, is faster and more prominent compared with Bet v 1a.

Protein crystallography of Bet v 1d reveals an overall three-dimensional structure similar to Bet v 1a with minor differences in electrostatic surface potential and an increased ability to form aggregates

To explore whether structural changes are responsible for the observed differences in BMDC stimulation, we determined the three-dimensional structure of Bet v 1d by X-ray crystallography and compared it with the previously published structure of Bet v 1a (19). As expected, the crystal structures of Bet v 1 isoforms a and d are very similar, because all amino acid exchanges can be easily accommodated in the structure (Fig. 8A). This is not surprising given the fact that both isoforms are naturally occurring in pollen. Analysis of the electrostatic surface potential indicates that mutation D126N results in a small reduction of negative surface potential in Bet v 1d (Fig. 8B). Although, this small change may alter affinity and recognition of Bet v 1d by Abs specific for Bet v 1a, it is very unlikely to be the main cause for the reduced allergenicity of Bet v 1d. In fact, we did not detect a difference in Ab recognition between the two isoforms. Furthermore, we investigated protein stability and aggregation behavior of Bet v 1a and d at conditions resembling immunological experiments. SDS-PAGE analysis revealed that Bet v 1d shows an increased tendency for self-aggregation. Coomassie brilliant blue staining of recombinant isoforms showed clear bands at 17 and 34 kDa corresponding to monomeric and dimeric protein only for Bet v 1d but not for Bet v 1a (Fig. 8C).

Dimeric Bet v 1d could also be identified in native BPEs (Fig. 8C). Using mass spectrometry, three of four peptides were exclusively of Bet v 1d origin (T1, AFILDDGLNVLPK; T3, YNYSVIEGPGVGDTELEK; T4, IVAPTDGGCVLK; T1 corresponds to amino acids A22–K33, T3 corresponds to amino acids Y82–K98, and T4 corresponds to amino acids I105–K116; amino acid sequences of Bet v 1a/d are shown in Fig. 1A). The fourth peptide (T2, VAPQAIGSVENIGGGPGTIK) could potentially derive from both isoforms. Despite the far higher abundance of Bet v 1a within BPEs, no Bet v 1a-specific peptide could be detected in the 34-kDa dimeric fraction.

Because dimeric Bet v 1d is not observed under reducing conditions, Bet v 1d forms disulfide-linked dimers because of the serine to cysteine exchange at position 113. Structural analysis showed that Cys113 is not surface exposed and thus only available for disulfide formation when Bet v 1d is at least partly unfolded. Online high-performance–size exclusion chromatography–light scattering, and DLS experiments revealed a higher polydispersity of Bet v 1d when compared with Bet v 1a indicating formation of aggregates. This elevated aggregation tendency was even more pronounced in the RPMI 1640 medium used for BMDC-uptake experiments (Fig. 8D). Consequently, increased aggregation due to stabilization of unfolded Bet v 1d contributes to enhanced BMDC activation.

Remutation of Cys113 of Bet v 1d abrogates dimerization and reverts Bet v 1d-specific immunological differences to Bet v 1a.

To show that increased aggregation, accompanied by altered immunologic properties correlates with Cys113, we remutated Cys113 to serine and generated protein Bet v 1d[Cys113Ser]. Indeed, analysis by SDS-PAGE revealed that the purified Bet v 1d[Cys113Ser] has lost its capacity to form homodimers (Fig. 9A).

Additionally, we tested the mutant protein Bet v 1d[Cys113Ser] for uptake by BMDCs (Fig. 9B) and determined an uptake efficacy of Bet v 1d[Cys113Ser] resembling that of Bet v 1a (Bet v 1a 32.7 ± 2.4% versus Bet v 1d 48.1 ± 3.2%, p < 0.001 versus Bet v 1d[Cys113Ser] 31.3 ± 1.9%, p = 0.2). Also analysis of the activation markers on stimulated BMDCs indicated that Bet v 1d[Cys113Ser] is comparable to Bet v 1a (CD80, 42.9 ± 6.3% for Bet v 1a, 85.1 ± 2.9% for Bet v 1d [p < 0.001] and 40.9 ± 0.7% for Bet v 1d[Cys113Ser]; [p = 0.3]; MHC II, 5.6 ± 2.2% for Bet v 1a, 13.3 ± 1.2% for Bet v 1d [p = 0.003] and 5.9 ± 1% for Bet v 1d[Cys113Ser] [p = 0.4]) (Fig. 9C).

Finally, we immunized mice with Bet v 1d[Cys113Ser] and compared specific serum IgG1 and IgE levels to Bet v 1a- and Bet v 1d-immunized mice on day 21. Intriguingly, immunization with the
CD4+ T cells purified from Bet v 1a (or no Ag, were incubated with specific Ag (Bet v 1a, were cocultured with CFSE-labeled syngeneic CD4+ T cells purified from Bet BMDCs were incubated with specific Ag (restim. Bet v 1a or Bet v 1d) and are shown (histogram. Representative FACS profiles from four independent experiments show the distribution and proliferation of the different Th subsets. Statistical analysis of experiments from Bet v 1a (mean ± SD; n = 4). (Abbreviations used as in Fig. 5.)

Bet v 1d[Cys113Ser] completely impeded the generation of high titers of specific serum IgG1, which we found characteristic for hypoallergenic Bet v 1d. Conversely, specific IgE levels remained comparable between Bet v 1a-, Bet v 1d-, and Bet v 1d[Cys113Ser]-immunized mice (Fig. 9D; Bet v 1-specific IgG1, 0.03 ± 0.05 for Bet v 1a versus 0.76 ± 0.81 for Bet v 1d [p = 0.01] versus 0.12 ± 0.34 for Bet v 1d[Cys113Ser] [p = 0.2]; Bet v 1-specific IgE, 2.4 ± 6.6 for Bet v 1a versus 5.8 ± 7.1 for Bet v 1d [p = 0.2] versus 0.2 ± 0.4 for Bet v 1d[Cys113Ser] [p = 0.2]).

We conclude that disulfide-based aggregation of Bet v 1d strongly increases immunogenicity and its potency to elicit a protective IgG1 response (Fig. 10).

Discussion

Naturally occurring and engineered recombinant allergens are becoming promising tools for immunotherapy of type I allergies, although the underlying mechanism is still matter of debate. Explanations range from a shift in the cytokine profile, impeding eosinophile recruitment and T cell-dependent late-phase responses, up to the induction of a protective IgG response in allergic individuals, thereby masking the specific allergen and thus avoiding its binding to specific effector cell-bound IgE (6, 20–22). To minimize the risk of side effects, allergen variants with reduced IgE binding capacity but preserved T cell reactivity—termed hypoallergenic derivatives—are recommended for safer immunotherapy (23, 24). Hypoallergens can either be genetically engineered “in vitro” or can emerge as natural isoforms from a distinct allergen. Regarding Bet v 1, the major allergen in birch pollen allergy, several natural isoforms exist, which show different IgE reactivity despite similar properties that define an allergen by comparing hyperallergenic Bet v 1 with hypoallergenic Bet v 1d. Because it was shown that

CD45FoxP3+ to CD45CD25FoxP3+ T cells is shown. Proliferating cells were defined as cells within the rectangular gates of FACS plots from bottom panel in D; n = 6. Mean ± SD; values of p indicated in graph (Wilcoxon test).
naturally occurring Bet v 1 proteins have no posttranslational modifications (4), the use of E. coli–produced recombinant Bet isoforms is legitimate. First, we asked whether the allergenicity of Bet v 1 isoforms can simply be attributed to their relative abundance in birch pollen (3). Therefore, we immunized mice with purified Bet v 1a and Bet v 1d, and we found that Bet v 1a induced a significantly weaker IgG1, IgG2a, and IgA response, whereas the amount of serum IgE was comparable (Fig. 1). In addition, we observed high cross-reactivity of serum Abs toward Bet v 1a and Bet v 1d (Fig. 2 and Supplemental Fig. 1), which we also found for mAbs derived from Bet v 1-specific hybridomas (Supplemental Table I). Hence, our results clearly indicate that hypoallergenic Bet v 1d has not lost its property to bind IgE but rather has gained the ability to induce a stronger immune response, as reflected by the presence of high-serum IgG and IgA Ab titers. These findings are in contrast with previous reports that ascribe hypoallergenicity primarily to the inability to bind human IgE from birch pollen-sensitized individuals, because of the exchange of seven amino acids that are exposed on the surface of the protein.

FIGURE 8. Crystal structure of Bet v 1d. A, Ribbon diagram color-coded from N terminus (blue) to C terminus (red) showing residues that differ between isoforms Bet v 1a and Bet v 1d in sticks. B, Electrostatic surface potential map (blue positive, red negative) of Bet v 1a left and Bet v 1d right. C, Coomassie brilliant blue-stained reducing and nonreducing SDS-PAGE of Bet v 1a and d and aqueous BPE. Bands corresponding to dimerized Bet v 1 are marked with an asterisk. The band from BPE corresponding to dimeric Bet v 1 was analyzed by nanoliquid chromatography–tandem mass spectrometry–based sequencing. Four Bet v 1-derived peptides were identified (T1, A22–K33; T2, V34–K55; T3, Y82–K98; T4, I105–K116), with T1, T3, and T4 being specific for Bet v 1d. D, DLS of Bet v 1a (solid black line) versus Bet v 1d (dashed gray line) in RPMI 1640 at 37°C (RH, hydrodynamic radius).

FIGURE 9. Mutation of Cys113 of Bet v 1d abrogates dimerization and reverts Bet v 1d-specific immunological properties. A, Bet v 1a, Bet v 1d, and Bet v 1d[Cys113Ser] were loaded on a reducing or nonreducing SDS-PAGE. The asterisk marks dimeric Bet v 1d. B, Ag uptake by BMDCs. BMDCs were incubated with FITC-Bet v 1a, FITC-Bet v 1d, or FITC-Bet v 1d[Cys113Ser]. One representative FACS profile is shown. Statistical analysis is given as mean ± SD; values of p are indicated in graph (n = 6). C, Expression of activation markers by BMDCs. Cells were gated for CD11c expression and the amount of CD80 and MHC II surface expression was determined. The graph shows the percentage of CD80 and MHC II-expressing cells within the Bet v 1-FITC–positive BMDCs. Mean ± SD; values of p are indicated in graph (unpaired Student t test) n = 3. D, Specific Ab response in mice. Mice were immunized with either Bet v 1a (dark gray circles), Bet v 1d[Cys113Ser] (light gray circles) or Bet v 1d (○) and boosted 2 wk after primary immunization. Serum was taken at day 21, and specific IgG1 and IgE serum titers were determined (n = 7–10). Values are shown as arbitrary units in comparison with a pooled standard serum. Mean values are given as dashed ± SD; values of p are indicated in graph (unpaired Student t test).
altered response to antigenic stimulation, associated with more finding that DCs from atopic individuals exhibit a significantly nature of antigenic stimulus (30–32). It has also been suggested influence of DCs on the Th1/Th2 polarization, depending on the it is not yet fully understood how DCs distinctively instruct the T cells to differentiate, recent reports described a substantial in-

(2, 5). To investigate the nature of the observed difference in immunogenicity of the two isoforms, we assessed their intrinsic property to stimulate BMDCs. Strikingly, we found that Bet v 1d was captured TLR4 and internalized by BMDCs at a higher rate (Fig. 3). The model Ag/allergen OVA (25) was captured at similar levels as Bet v 1a together with similar expression of CD80 and MHC II on BMDCs (Supplemental Fig. 2), we hypothesize that weak DC activation is a general feature of allergens.

Furthermore, the expression of activation markers CD80, CD86, and MHC II was significantly higher in BMDCs stimulated with Bet v 1d as compared with Bet v 1a (Fig. 4), whereas IL-6 produc-

tion was more pronounced in BMDCs stimulated with Bet v 1a (Fig. 5). Interestingly, increased IL-6 levels have been associated with human atopic asthma, and recently, IL-6 was proposed to be essential for mucosal hypersecretion by airway epithelial cells in response to inhaled allergens (26), which would suit to our finding of increased IL-6 production triggered by hyperallergic Bet v 1a. In addition, IL-6 was shown to dampen Ag-mediated DC maturation/activation (27). Taken together with our data, it is conceivable that insufficient DC activation increases the propensity for allergic immune responses.

DCs play a pivotal role in the immune response by taking up Ag and providing information about its pathogenicity to other immune cells, thereby activating or tolerizing Ag-specific T cells and producing proinflammatory cytokines (28). Ag uptake is performed either by macro-pinocytosis or specifically by receptor-mediated endocytosis by virtue of FcRs, by multiple lectin domain-bearing transmembrane receptors like mannose receptor or DEC205 molecule, or by surface glycoproteins (29). Although, it is not yet fully understood how DCs distinctively instruct the T cells to differentiate, recent reports described a substantial influence of DCs on the Th1/Th2 polarization, depending on the nature of antigenic stimulus (30–32). It has also been suggested that DCs derived from different tissue are characterized by different T cell-polarizing properties (33–35) in addition to the finding that DCs from atopic individuals exhibit a significantly altered response to antigenic stimulation, associated with more effective production of Th2-type cytokines (36, 37). Upon stimulation with TLR9-dependent stimuli, DCs from atopic subjects respond with a vastly reduced production of IFN-α (38). As DCs are potent producers of the Th1-supportive cytokine IL-12, DCs from atopic individuals were reported to induce Th2 differentiation by an insufficient production of IL-12 (39), which contrasts other findings that DCs derived form allergic patients show increased levels of IL-13 production when stimulated in vitro with allergenic determinants (40), which triggers Th2 differentiation independent from IL-12 (36). In our own experiments, we could not detect any difference in the IL-12/23 production by BMDCs upon stimulation with Bet v 1a or Bet v 1d (Fig. 5). It is also discussed that in atopic patients, the presence of allergic mediators like histamine modulates the capacity of DCs to instruct T cells for differentiation (41). Our finding that Bet v 1d is more effectively captured by BMDCs indicates that aggregation facilitates nonspecific uptake or specific binding to distinct transmembrane receptors.

We also observed an altered T cell proliferation and differentiation in syngeneic BMDC-T cell coculture experiments when Bet v 1a or Bet v 1d was used as Ag. Although the overall proliferation of Bet v 1-specific T cells was not dramatically different in response to Bet v 1a- or Bet v 1d-pulsed BMDCs (Fig. 6C), Bet v 1d induced an increase in the generation of IL-13–producing Th1 and 2 cells and a decrease in the proliferation of FoxP3+CD25+ Tregs (Fig. 6E–H). This finding was surprising, because it contrasts recent reports on allergen-specific Tregs as being crucial for the healthy nonatopic immune response and that the generation of specific Tregs is a key event for successful immunotherapy (42, 43). Alternatively, a too early suppression of the immune response by Tregs, as seen for Bet v 1a, might negatively influence the induction of a protective Ig isotype repertoire. Our observations lead to the interpretation that Bet v 1a is less immunogenic than Bet v 1d, reflected in minor activation of BMDCs in vitro and thus leading to the induction of lower Th2 numbers and higher levels of Tregs. Accordingly, previous studies have already demonstrated that Treg differentiation is driven by reduced expression of CD80 and CD86 costimulatory molecules on BMDCs (44, 45).

Also, the profile of cytokine expression of T cells from coculture assays varied according to the Ag used for BMDCs pulsing. T cells from Bet v 1a-immunized mice cultured in the presence of Bet v 1d-loaded BMDCs responded with the secretion of significantly higher amounts of IFN-γ, IL-4, and IL-5 compared with BMDCs pulsed with Bet v 1a. Using T cells form Bet v 1d-immunized mice in coculture with Bet v 1d-pulsed BMDCs, all five cytokines were significantly increased compared with Bet v 1a-loaded BMDCs (Fig. 7). We next looked for differences in the three-dimensional structure of Bet v 1 isoforms. However, the X-ray crystal structure of Bet v 1d revealed no significant difference to the structure of Bet v 1a (Fig. 8). However, analysis of the electrostatic surface potential indicated that mutation D125N resulted in a small reduction of negative surface potential in Bet v 1d. Although this minimal exchange may alter affinity and recognition of Bet v 1d by Igs, it is very unlikely to have an effect on dendritic phagocytosis. It is, however, conceivable that increased aggregation, which is indeed observed for purified Bet v 1d is the reason for this phenomenon. This increased self-aggregation is either caused by altered surface potentials or decreased protein stability. SDS-PAGE analysis revealed that a significant fraction of Bet v 1d forms disulfide-linked dimers because of the serine to cysteine exchange at position 113. In fact, high molecular weight aggregates (30–100 Bet v 1d molecules) were observed by DLS under physiological conditions. Formation of such aggregates may be promoted by partial un-

FIGURE 10. Illustration of the Ab response toward Bet v 1a (A) and Bet v 1d (B). A. Monomeric Bet v 1a provides only low stimulus to APCs, leading to incomplete APC activation and therefore to a higher induction of Tregs with only moderate Ab levels. Because of the absence of a protective IgG/IgA Ab response, serum IgE levels are sufficient to trigger allergic symptoms. B. As a result of self-aggregation, Bet v 1d is more immunogenic reflected by the induction of higher costimulatory molecules, thereby inducing a strong Th1/Th2-dependent Ab response with high levels of protective IgG/IgA Abs for Ag clearance.


of both IL-4 and IFN-γ from primary cultures of naive CD4+ T cells in a dose-dependent manner. Cytotechnology 43: 49–55.


Corrections


The authors wish to retract the crystallographic section of this article, in particular Fig. 8A (ribbon diagram of the crystal structure of Bet v 1d) and Fig. 8B (electrostatic surface potential map of Bet v 1a, left, and Bet v 1d, right).

An analysis published in *Acta Crystallographica Section F.* 68: 4, p. 366–376 resulted in an investigation by the Austrian Agency for Research Integrity. The Austrian Agency for Research Integrity has confirmed that Robert Schwarzenbacher concedes he committed scientific misconduct concerning the crystallographic data in this article. Furthermore, the Austrian Agency for Research Integrity confirms that the other data in the article are valid and that there is no suspicion of scientific misconduct apart from that in Fig. 8A and Fig. 8B.

The Protein Data Bank has been informed and has retracted the 3K78 entry.

Retraction of the crystallographic section does not affect the major conclusions of the article.

www.jimmunol.org/cgi/doi/10.4049/jimmunol.1390013